Key Points
Question Is long-term treatment with acoramidis in transthyretin amyloid cardiomyopathy associated with sustained clinical benefit through 54 months in the open-label extension of ATTRibute-CM?
Findings Among 389 participants enrolled in the open-label extension of the ATTRibute-CM randomized clinical trial, early and continuous acoramidis treatment was associated with sustained reductions in all-cause mortality, cardiovascular-related mortality, and first cardiovascular hospitalization, with consistent benefit across prespecified demographic and clinical subgroups. Biomarkers, functional capacity, and health status remained stable or improved, and no new long-term safety concerns were identified.
Meaning These findings support early and continuous acoramidis treatment to achieve long-term disease stabilization in transthyretin amyloid cardiomyopathy.